Stephen Rubino
Direttore/Membro del Consiglio presso VIRACTA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Stephen Rubino
Società | Posizione | Inizio | Fine |
---|---|---|---|
VIRACTA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 03/03/2021 | - |
Independent Dir/Board Member | 03/03/2021 | - | |
Sermonix Pharmaceuticals LLC
Sermonix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sermonix Pharmaceuticals LLC operates as a pharmaceutical company that focuses on the development and commercialization of late-stage women?s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 by David Portman and is headquartered in Columbus, OH. | Direttore/Membro del Consiglio | - | - |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Presidente | - | - |
Storia della carriera di Stephen Rubino
Precedenti posizioni note di Stephen Rubino
Società | Posizione | Inizio | Fine |
---|---|---|---|
CELYAD ONCOLOGY SA | Corporate Officer/Principal | 01/02/2020 | 01/04/2022 |
ILKOS THERAPEUTICS, Inc.
ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Direttore/Membro del Consiglio | 01/01/2017 | 01/02/2020 |
OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2018 | 01/05/2019 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/01/2001 | 01/01/2017 |
Schering-Plough Europe SA | Corporate Officer/Principal | 01/09/1991 | 01/06/2001 |
Formazione di Stephen Rubino
Baruch College | Masters Business Admin |
Weill Cornell Medical College | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Belgio | 3 |
Canada | 2 |
Posizioni
Director/Board Member | 4 |
Corporate Officer/Principal | 4 |
Doctorate Degree | 1 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
OMEGA THERAPEUTICS, INC. | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Schering-Plough Europe SA | |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
ILKOS THERAPEUTICS, Inc.
ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Health Technology |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
Sermonix Pharmaceuticals LLC
Sermonix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sermonix Pharmaceuticals LLC operates as a pharmaceutical company that focuses on the development and commercialization of late-stage women?s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 by David Portman and is headquartered in Columbus, OH. | Health Technology |
- Borsa valori
- Insiders
- Stephen Rubino
- Esperienza